BIOmarkers and PREDISC Diagnostic Evaluation for Patients With Suspected Transient Ischemic Attacks: the BIOPREDISC- TIA SWISS Cohort Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Cerebrovascular Disease, Ischemic Stroke
- Sponsor
- Dr. med. Carlo Cereda
- Enrollment
- 64
- Locations
- 2
- Primary Endpoint
- Levels of specific biomarkers (Platelet Basic Protein (PBP), ceruloplasmin, microRNAs, exosomal particles) in patients with suspected TIA.
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
This research project aims at contributing to improve TIA diagnosis and management by using PREDISC scores and specific biomarkers thought to have elevated levels in TIA patients. A swift and accurate TIA diagnosis allows starting treatment of the patient adequately and shortly after the event. The shorter the time between the event and treatment onset, the better the outcome. This approach will be an important step forward in TIA diagnosis and management, similarly to acute coronary syndrome as discussed above.
Investigators
Dr. med. Carlo Cereda
MD Capo Servizio
Ospedale Civico, Lugano
Eligibility Criteria
Inclusion Criteria
- •Patients with suspected TIA (defined as the acute onset of focal neurological symptoms lasting \<24 h and presumed to be caused by brain ischemia at the time of referral) within 48 h of symptoms onset.
- •At least 18 years old.
- •Having given their Informed Consent.
Exclusion Criteria
- •· Patients with ocular TIA (Amaurosis fugax).
- •Patients that still have neurological deficits at the moment of inclusion.
- •Contraindication to perform MRI.
- •For women: pregnancy.
Outcomes
Primary Outcomes
Levels of specific biomarkers (Platelet Basic Protein (PBP), ceruloplasmin, microRNAs, exosomal particles) in patients with suspected TIA.
Time Frame: 1 year
Diagnostic performance according to PREDISC scale